Gabardi S - Search Results

1

Current trends in immunosuppressive therapies for renal transplant recipients.

Lee RA, Gabardi S. Lee RA, et al. Among authors: gabardi s. Am J Health Syst Pharm. 2012 Nov 15;69(22):1961-75. doi: 10.2146/ajhp110624. Am J Health Syst Pharm. 2012. PMID: 23135563 Review.

2

Induction immunosuppressive therapies in renal transplantation.

Gabardi S, Martin ST, Roberts KL, Grafals M. Gabardi S, et al. Am J Health Syst Pharm. 2011 Feb 1;68(3):211-8. doi: 10.2146/ajhp090636. Am J Health Syst Pharm. 2011. PMID: 21258026 Review.

3

Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.

Gabardi S, Asipenko N, Fleming J, Lor K, McDevitt-Potter L, Mohammed A, Rogers C, Tichy EM, Weng R, Lee RA. Gabardi S, et al. Transplantation. 2015 Jul;99(7):1499-505. doi: 10.1097/TP.0000000000000570. Transplantation. 2015. PMID: 25643140

4

Assessing pharmacologic and nonpharmacologic risks in candidates for kidney transplantation.

Maldonado AQ, Tichy EM, Rogers CC, Campara M, Ensor C, Doligalski CT, Gabardi S, Descourouez JL, Doyle IC, Trofe-Clark J. Maldonado AQ, et al. Among authors: gabardi s. Am J Health Syst Pharm. 2015 May 15;72(10):781-93. doi: 10.2146/ajhp140476. Am J Health Syst Pharm. 2015. PMID: 25941253 Review.

5

Pharmacoepidemiology of anemia in kidney transplant recipients.

Winkelmayer WC, Kewalramani R, Rutstein M, Gabardi S, Vonvisger T, Chandraker A. Winkelmayer WC, et al. Among authors: gabardi s. J Am Soc Nephrol. 2004 May;15(5):1347-52. doi: 10.1097/01.asn.0000125551.59739.2e. J Am Soc Nephrol. 2004. PMID: 15100376

6

Treating gout in kidney transplant recipients.

Baroletti S, Bencivenga GA, Gabardi S. Baroletti S, et al. Among authors: gabardi s. Prog Transplant. 2004 Jun;14(2):143-7. doi: 10.1177/152692480401400208. Prog Transplant. 2004. PMID: 15264458 Review.

7

Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.

Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK. Gabardi S, et al. Pharmacotherapy. 2004 Oct;24(10):1323-30. doi: 10.1592/phco.24.14.1323.43152. Pharmacotherapy. 2004. PMID: 15628830

8

Analysis of infusion-site reactions in renal transplant recipients receiving peripherally administered rabbit antithymocyte globulin as compared with basiliximab.

Erickson AL, Roberts K, Malek SK, Chandraker AK, Tullius SG, Gabardi S. Erickson AL, et al. Among authors: gabardi s. Transpl Int. 2010 Jun;23(6):636-40. doi: 10.1111/j.1432-2277.2009.01042.x. Epub 2010 Jan 13. Transpl Int. 2010. PMID: 20074083 Free article.

9

Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation.

Martin ST, Tichy EM, Gabardi S. Martin ST, et al. Among authors: gabardi s. Pharmacotherapy. 2011 Apr;31(4):394-407. doi: 10.1592/phco.31.4.394. Pharmacotherapy. 2011. PMID: 21449628 Review.

10

Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.

Gabardi S, Catella J, Martin ST, Perrone R, Chandraker A, Magee CC, McDevitt-Potter LM. Gabardi S, et al. Ann Pharmacother. 2011 Sep;45(9):e48. doi: 10.1345/aph.1Q019. Epub 2011 Aug 2. Ann Pharmacother. 2011. PMID: 21811001

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

81 results

Search Page

Filters